A drug named Nurtec ODT by Biohaven Pharma had acquired the 10th position. FDA had given the nod on February 27 2020. It was produced for the acute treatment of migraine or without aura in adults. The total sale for the year 2020 was $28.513 million from this medicine.
A product called Zepzelca had secured the 9th position, developed for the patients with metastatic small-cell lung cancer with disease progression. Jazz Pharma had received the approval from US FDA on June 15 2020. The total sale achieved by the company from this drug in the year 2020 was $36.9 million.
REGEN-COV2 by Regeneron Pharma was in 8th position. The company had made the drug for the treatment of mild to moderate Covid-19 in adult patients. FDA had approved the Regeneron’s Covid drug on 21st November 2020. It generated sales revenue of $40.2 million.
Abbvie’s Ubrelvy was in 7th position. This drug is indicated for the treatment of adult patients with migraines or without aura. United States FDA had approved the drug on December 23 2018. It had brought total sales of around $60 million in 2020.
Novartis’s Adakveo was in 6th position. Pharma giant had received the nod from the FDA on November 15 2019. The drug was made to reduce the frequency of vaso-occlusive crises in adolescent patients. Around $71 million of sales it had brought in 2020.
A drug by Immunomedics for the treatment of patients above 18 years of age with metastatic triple-negative breast cancer enabled them to bag the 5th position in this segment. FDA had approved Immunomedics’s Trodelvy on 22nd April 2020. A total sale of $73 million was made from this product.
Pfizer’s Ruxience was in 4th position. Drug was developed for the patients with Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis.US Drug regulator had approved the drug on 23rd July 2019. A total of $ 78 million in sales was brought from this drug.
The drug that had secured the 3rd position in 2020 was Reblozyl. Bristol Myers Squibb and Acceleron Pharma were the producers. Both pharma companies had received the nod from a US-based drug regulator on 8th November 2019. $159 million of sales it had brought for the company.
Horizon Therapeutics’s drug named Tepezza for thyroid eye disease had bagged the 2nd position. FDA approved it on 21st Jan 2020. This company had made over $475 million of sales from this product.
Gilead Sciences’ product named Veklury was in 1st position. This drug was made for adult and pediatric Covid patients who required hospitalization. It was approved by the USFDA on 22nd October 2020. $873 million of sales was achieved from this drug.